What are the opening hours?

Monday 10am - 3pm Tuesday 10am - 3pm Wednesday 10am - 3pm Thursday 10am - 3pm

Metanalyses, Gateway Circular Quay, Sydney/Office Level 36, Gateway 1 Macquarie Place, North Sydney (2026)

30/12/2025

🅜🅔🅣🅐 Published Today (December 29, 2025) - This study evaluates the efficacy and safety of upadacitinib compared to other systemic treatments for moderate-to-severe atopic dermatitis, focusing on skin clearance and itch reduction. TITLE: EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

🅼 Link: https://doi.org/10.1038/s41598-025-28756-2

🅼 Key Findings:

Upadacitinib (30 mg) demonstrated superior skin clearance (EASI-75) compared to dupilumab and other JAK inhibitors.

Both 15 mg and 30 mg doses of upadacitinib significantly improved pruritus (itch) scores within the first few weeks of treatment.

The safety profile of upadacitinib was found to be manageable, with common adverse events including acne and upper respiratory tract infections.

Network meta-analysis ranked upadacitinib 30 mg as the most effective intervention for achieving EASI-90 and EASI-100 responses.

Results remained consistent across various patient subgroups, confirming robust efficacy in diverse clinical settings for atopic dermatitis.

While highly effective, the study highlights the necessity of monitoring for JAK-related adverse events during long-term administration.

🅼 Clinical Relevance

Upadacitinib offers a potent oral alternative for patients with moderate-to-severe atopic dermatitis who fail to respond to traditional therapies. Its rapid onset of action in reducing itch and achieving high levels of skin clearance makes it a valuable option in dermatological practice. Clinicians should balance these high efficacy rates with individualized patient safety monitoring.

Isa. 41:10: | Ghost Crafted by Meta Pro!

29/12/2025

Got medical research? Hand it over to Metanalyses 🧠📊

We handle the heavy work—analysis, synthesis, and clear results—so you don’t have to. No fluff. Just solid research support.

29/12/2025

🅜🅔🅣🅐 Published December 28, 2025 - This meta-analysis evaluates the efficacy and safety of GLP-1 receptor agonists combined with SGLT2 inhibitors for treating type 2 diabetes and metabolic-associated fatty liver disease.

TITLE: EFFICACY AND SAFETY OF GLP-1 RECEPTOR AGONISTS COMBINED WITH SGLT2 INHIBITORS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND METABOLIC-ASSOCIATED FATTY LIVER DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

🅼 Link: https://doi.org/10.1186/s12933-025-03048-1

🅼 Key Findings:

• The combination therapy shows a superior reduction in HbA1c levels compared to monotherapy or placebo in T2DM patients.

• Significant improvements were noted in body weight and body mass index, highlighting the weight-loss synergy of these drug classes.

• Liver enzymes, specifically ALT and AST, showed marked decreases, indicating a reduction in liver inflammation and fat accumulation.

• Non-invasive markers for liver fibrosis and steatosis improved significantly, suggesting regression of MAFLD progression.

• Cardiovascular risk factors, including blood pressure and lipid profiles, were favorably impacted by the combined treatment regimen.

• The safety profile remained consistent with individual therapies, with gastrointestinal issues being the most common but manageable side effects.

• Combining these agents provides a comprehensive approach to managing the multi-organ complications of metabolic syndrome.

🅼 Clinical Relevance

Clinicians should consider dual GLP-1 RA and SGLT2i therapy for patients with co-existing T2DM and MAFLD. This approach not only optimizes glycemic control but specifically targets the hepatic and cardiovascular comorbidities common in this population. The synergy between these classes offers a potent tool for weight management and long-term organ protection in complex metabolic cases.

Isa. 41:10: | Ghost Crafted by Meta Pro!

29/12/2025

🅜🅔🅣🅐 Published Today (December 27, 2024) - This meta-analysis evaluates the diagnostic accuracy of AI models in identifying multiple sclerosis from MRI scans, highlighting their potential for clinical decision support systems globally.

TITLE: DIAGNOSTIC ACCURACY OF ARTIFICIAL INTELLIGENCE MODELS FOR MULTIPLE SCLEROSIS ON MAGNETIC RESONANCE IMAGING: A SYSTEMATIC REVIEW AND META-ANALYSIS

🅼 Link: https://doi.org/10.1038/s41746-025-02266-x

🅼 Key Findings:

‘’ The study reveals that AI models demonstrate high sensitivity and specificity in detecting MS lesions on MRI, often performing comparably to or exceeding the diagnostic accuracy of experienced radiologists.

‘’ Deep learning architectures, particularly convolutional neural networks (CNNs), showed superior performance in lesion segmentation and classification compared to traditional machine learning methods.

‘’ The meta-analysis highlights significant heterogeneity among studies, emphasizing the need for standardized protocols in data acquisition and AI model validation across different clinical settings.

‘’ Results indicate that AI-integrated workflows can significantly reduce the time required for MRI interpretation, potentially accelerating the diagnostic journey for patients with suspected MS.

‘’ Despite high performance, the research underscores that AI should serve as a supportive tool rather than a replacement for clinical judgment and expert neurological evaluation.

🅼 Clinical Relevance

AI integration in MS diagnostics offers a transformative approach to neuroradiology. By providing objective, rapid, and precise lesion analysis, these models can assist clinicians in earlier diagnosis and more accurate monitoring of disease progression. This is particularly vital in resource-limited settings where access to specialized neuroradiologists may be restricted.

Isa. 41:10: | Ghost Crafted by Meta Pro!

28/12/2025

⏰ Doctors, your time is priceless.

Metanalyses helps you reclaim it.

Let us handle your medical research and writing so you get:

❤️ More time with loved ones

📚 More time for learning

👩‍⚕️ More time for patients

💆 More time for yourself

🏋️ More time for exercise

😴 More time for rest

More time for everything that truly matters.

27/12/2025

🚀 Calling all Medical Students, Physicians, and Doctoral Researchers! 🩺📚

Are you working on:

✅ Case Reports

✅ Case Series

✅ Cross‑Sectional Studies

✅ Case‑Control Studies

✅ Cohort Studies (Prospective & Retrospective)

✅ Randomized Controlled Trials (RCTs)

✅ Quasi‑Experimental Studies

✅ Diagnostic Accuracy Studies

✅ Prognostic Studies

✅ Health Services / Outcomes Research

✅ Quality Improvement Research

✅ Epidemiological Studies

✅ Public Health / Community‑Based Research

✅ Translational / Bench‑to‑Bedside Research

✅ Clinical Audits

✅ Systematic Reviews

✅ Meta‑Analyses

The Metanalyses Team 🧠—a group of PhD and MD specialists—can support you at every step:

📝 Protocol development & research questions

📊 Study design & methodology

🧮 Sample size & power calculations

🧷 Data collection tools & database setup

📈 Biostatistics & advanced data analysis

📃 Manuscript writing, editing, and journal formatting

📑 Systematic review & meta‑analysis planning, ex*****on, and reporting

Whether you’re a:

👨‍⚕️ Medical student

👩‍⚕️ Practicing physician

🎓 PhD or other doctorate trainee

…we’re here to help you produce rigorous, publishable research.

📩 Send us a message to collaborate with the Metanalyses Team and take your research to the next level!

27/12/2025

🅜🅔🅣🅐 Published Today December 26, 2025 - This meta-analysis evaluates the efficacy of digital health interventions in improving glycemic control for patients with type 2 diabetes across diverse global healthcare settings. TITLE: EFFECTIVENESS OF DIGITAL HEALTH INTERVENTIONS FOR GLYCEMIC CONTROL IN TYPE 2 DIABETES: A SYSTEMATIC REVIEW AND META-ANALYSIS

🅼 Link: https://doi.org/10.1038/s41467-025-67372-6

🅼 Key Findings:

Digital health tools significantly reduce HbA1c levels compared to standard care, showing a mean difference of -0.45%.

Mobile applications and SMS-based interventions demonstrated the highest engagement and effectiveness among participants.

Continuous glucose monitoring integration within digital platforms provided superior outcomes in long-term glucose stability.

The study highlights that personalized digital feedback loops are critical for maintaining patient adherence to treatment.

Benefits were consistent across various age groups, though younger populations showed faster adaptation to the technology.

Scalability of these digital interventions offers a cost-effective solution for over-burdened healthcare systems worldwide.

🅼 Clinical Relevance

Clinicians should integrate digital health platforms into routine diabetes management to enhance patient self-efficacy and glycemic outcomes. These tools provide real-time data that allow for more precise medication adjustments and lifestyle coaching, bridging the gap between clinical visits and daily self-care for better long-term health.

Isa. 41:10: | Ghost Crafted by Meta Pro!

27/12/2025

We are thrilled to announce that the Metanalyses team is collaborating with Isomorphic Labs (Iso) to push the boundaries of medical research! 🚀🧬

By applying our deep expertise in meta-analysis, we are supporting their groundbreaking work in AI-driven drug discovery. Together, we are working to validate data, unlock new insights, and accelerate the path to faster breakthroughs and cures for diseases. 💊💻

The future of medicine is here, and we are proud to be part of it.

26/12/2025

🅜🅔🅣🅐 Published Today December 25, 2025 - This meta-analysis evaluates the efficacy and safety of tramadol for chronic pain, revealing that its minimal pain relief is outweighed by a significantly increased risk of serious adverse events. TITLE: TRAMADOL VERSUS PLACEBO FOR CHRONIC PAIN: A SYSTEMATIC REVIEW WITH META-ANALYSIS AND TRIAL SEQUENTIAL ANALYSIS

🅼 Link: https://doi.org/10.1136/bmjebm-2025-114101

🅼 Key Findings:

• Analysis of 19 trials with 6,506 patients shows tramadol provides only a slight reduction in chronic pain levels.

• The pain relief observed was below the threshold for a minimal clinically important difference for most patients.

• Tramadol use is associated with a 2.13-fold increase in the risk of serious adverse events compared to placebo.

• Serious harms were primarily driven by cardiac events, including chest pain and congestive heart failure.

• Moderate certainty evidence indicates a significant increase in both serious and non-serious adverse outcomes.

• Common side effects include nausea (NNH 7), dizziness (NNH 8), constipation (NNH 9), and somnolence (NNH 13).

• There is no conclusive evidence that tramadol improves quality of life or physical function in chronic pain.

• Researchers suggest that the potential harms of tramadol likely outweigh its limited analgesic benefits.

🅼 Clinical Relevance

Clinicians should reconsider tramadol as a first-line treatment for chronic pain due to its poor risk-benefit profile. The modest pain relief does not justify the doubled risk of serious cardiac events and common side effects. Practitioners are encouraged to prioritize safer non-opioid alternatives and reserve tramadol only for specific cases where other options are unsuitable or ineffective.

Isa. 41:10: | Ghost Crafted by Meta Pro!

25/12/2025

Headline: The Numbers Don't Lie—Your Patients Need You More Than Your Paperwork Does.

Did you know that in the Philippines, there are only 3 doctors for every 10,000 Filipinos? (source https://doi.org/10.4082/kjfm.25.0043 March 2025)

That is a staggering gap. Every minute you spend stuck behind a computer wrestling with data, citations, and manuscript formatting is a minute taken away from a patient who is waiting for your care.

We know that research is a vital part of your Fellowship and training. But in a healthcare system stretched this thin, your clinical skills are your most valuable resource.

Don't let the burden of medical writing keep you from the bedside.

At Metanalyses, we are here to help Medical Students and Doctors in Fellowship unload the weight of research and writing. ✅ Expert assistance with systematic reviews & meta-analyses ✅ Streamlined medical writing support ✅ More time for you to focus on what matters most: Saving Lives.

You handle the healing. Let us help handle the writing.

📩 Message us today to learn how we can support your research requirements.

25/12/2025

🅜🅔🅣🅐 Published Today (December 24, 2025) - This meta-analysis evaluates the efficacy and safety of next-generation therapies for patients with advanced solid tumors, focusing on progression-free survival and adverse event profiles. TITLE: EFFICACY AND SAFETY OF NEXT-GENERATION THERAPIES IN ADVANCED SOLID TUMORS: A SYSTEMATIC REVIEW AND META-ANALYSIS

🅼 Link: https://doi.org/10.1038/s43856-025-01296-6

🅼 Key Findings:

• Next-generation targeted therapies demonstrated a statistically significant improvement in progression-free survival across various solid tumor types compared to standard-of-care treatments.

• The analysis revealed a higher objective response rate in patients receiving personalized medicine protocols guided by comprehensive genomic profiling versus conventional chemotherapy.

• Safety profiles remained manageable, though a higher incidence of grade 3/4 skin toxicity was observed in specific cohorts receiving epidermal growth factor receptor inhibitors.

• Subgroup analysis indicated that patients with specific biomarkers showed the most profound clinical benefit, suggesting the importance of early molecular screening in treatment.

• Long-term follow-up data suggested a trend toward improved overall survival, although further longitudinal studies are required to confirm the durability of these outcomes.

🅼 Clinical Relevance

This study underscores the shift toward precision oncology, providing clinicians with evidence-backed strategies for selecting targeted agents. It highlights the necessity of integrating genomic testing into routine practice to optimize patient outcomes and minimize unnecessary toxicity from broad-spectrum treatments, ultimately improving the quality of life for those with advanced cancers.

Isa. 41:10: | Ghost Crafted by Meta Pro!

24/12/2025

🅜🅔🅣🅐 Published Today (December 23, 2025) - This meta-analysis evaluates the efficacy of tranexamic acid (TXA) in reducing blood loss and transfusion requirements for patients undergoing major abdominal surgeries. TITLE: EFFICACY OF TRANEXAMIC ACID IN REDUCING BLOOD LOSS AND TRANSFUSION REQUIREMENTS IN MAJOR ABDOMINAL SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS

🅼 Link: https://doi.org/10.1177/00031348251403589

🅼 Key Findings:

‘’ TXA significantly reduces the volume of intraoperative and postoperative blood loss compared to placebos in major abdominal procedures.

‘’ The administration of TXA is associated with a lower risk of requiring allogeneic blood transfusions, preserving patient blood volume.

‘’ No significant increase in the risk of thromboembolic events, such as deep vein thrombosis or pulmonary embolism, was found with TXA use.

‘’ The meta-analysis suggests that TXA is a safe and cost-effective pharmacological intervention for improving surgical outcomes.

‘’ Results indicate consistent benefits across various abdominal sub-specialties, including hepatobiliary and colorectal surgeries.

‘’ TXA treatment leads to higher postoperative hemoglobin levels, facilitating faster patient recovery and shorter hospital stays.

🅼 Clinical Relevance

TXA serves as a critical tool in blood management protocols for major abdominal surgery. By minimizing blood loss and the need for transfusions without increasing clotting risks, it enhances patient safety, reduces healthcare costs, and mitigates risks associated with blood transfusions. Surgeons should consider routine TXA use to optimize perioperative care and improve surgical recovery.

Isa. 41:10: | Ghost Crafted by Meta Pro!

Metanalyses

30/12/2025

29/12/2025

29/12/2025

29/12/2025

28/12/2025

27/12/2025

27/12/2025

27/12/2025

26/12/2025

25/12/2025

25/12/2025

24/12/2025

Address

Opening Hours

Telephone

Website

Alerts

Contact The Business

Shortcuts

Share

Category

Monday	10am - 3pm
Tuesday	10am - 3pm
Wednesday	10am - 3pm
Thursday	10am - 3pm